At City of Hope, we are actively developing tomorrow’s treatment protocols today for prostate cancer. As a patient at City of Hope, you have a highly experienced and dedicated team to treat you and help you cope with cancer.
Our involvement in managing a patient’s prostate cancer starts very early and includes all stages of disease, ranging from localized to recurrent and advanced prostate cancer. City of Hope’s Prostate Cancer Program focuses on providing the most advanced, compassionate, multidisciplinary care to patients with various stages of prostate cancer while actively investigating promising new treatment strategies.
Our innovative treatment options and technologies can help you recover faster, with fewer side effects. Also setting us apart:
City of Hope is a world leader in high-precision, robotic-assisted prostate surgery, and our doctors have performed more advanced procedures for prostate cancer than any other facility on the West Coast.
Our team of experts was the first in the western United States to offer TomoTherapy — a targeted radiation therapy that can kill cancer cells while sparing healthy tissues nearby.
We aggressively pursue and use the newest, most innovative treatments known, including novel research therapies not available elsewhere.
About Active Surveillance
There has been some debate about the value of regular prostate-cancer screening (prostate-specific antigen, or PSA, test), especially in men who have been diagnosed with prostate cancer. Many prostate cancers do not require immediate treatment because they are small, confined and slow growing. Aggressive treatment may be more disruptive to a man’s quality of life than "active surveillance," which closely monitors patients to detect early signs of disease progression and enables treatment before the cancer has spread beyond the prostate. For those men with low-grade tumors, City of Hope specialists may recommend active surveillance. Our specialists will determine the best course of treatment balanced with each man’s vision of a quality life beyond diagnosis.
City of Hope has been an innovator in diagnostic research to more precisely track the progression of prostate cancer. Our researchers have developed a test using the TMPRSS2:ERG marker that supplements the PSA test and more accurately indicates if a biopsy is needed. The research was published in 2008 in the journal Clinical Chemistry in Work and presented at the Western Section of the American Urological Association Conference in 2013. Our researchers have discovered new markers for prostate cancer that will improve our ability to detect prostate cancer without a biopsy.
City of Hope ascribes to the American Urologic Association’s newest guidelines for prostate cancer screening, published in May 2013.
From diagnosis and treatment to recovery, prostate cancer patients at City of Hope have access to all of the best tools and strategies for beating the disease.